AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24463662 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations ≥75 nmol/L
Number of subjects: 792
Study 24463662 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations ≥50 nmol/L in white women
Number of subjects: 792
Study 24463662 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations ≥50 nmol/L in nonobese women
Number of subjects: 792
Study 21788541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led transitional care program
Number of subjects: 0
Study 21788541 — intervention group
Group type: COMPARATOR
Intervention: Other hospitals within the Baylor Health Care System (control)
Number of subjects: 0
Study 18829689 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary care group (multi-disciplinary assessment in a day hospital)
Number of subjects: 505
Study 18829689 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care group (nurse-led assessment and targeted referral)
Number of subjects: 505
Study 18829689 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 505
Study 17317184 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast MRI
Number of subjects: 491
Study 17317184 — intervention group
Group type: COMPARATOR
Intervention: XRM (mammography +/‐ ultrasound)
Number of subjects: 491
Study 15220883 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with arthroscopic subacromial decompression (group 1)
Number of subjects: 93
Study 15220883 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic rotator cuff repair without arthroscopic subacromial decompression (group 2)
Number of subjects: 93
Study 10893378 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.01 mg/kg body weight, IM injection)
Number of subjects: 217
Study 10893378 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.005 mg/kg, IM injection)
Number of subjects: 217
Study 10893378 — intervention group
Group type: COMPARATOR
Intervention: Saline solution placebo (approximately 2 mL, IM injection)
Number of subjects: 217
Study 8941060 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH (75 IU) + GH (0.1 IU/kg IM for 3 days)
Number of subjects: 24
Study 8941060 — intervention group
Group type: COMPARATOR
Intervention: FSH (75 IU)
Number of subjects: 24
Study 8941060 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24
Study 8941060 — intervention group
Group type: COMPARATOR
Intervention: GH alone
Number of subjects: 24
Study 1546817 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (110, 220, or 440 microgram)
Number of subjects: 304
Study 1546817 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (440 microgram)
Number of subjects: 304
Study 1546817 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 304
Study 1546817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 2408513 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (1 in 1,000 and 1 in 10,000)
Number of subjects: 60
Study 2408513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (1 in 1,000)
Number of subjects: 60
Study 2408513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine (1 in 1,000)
Number of subjects: 60
Study 2408513 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (1 in 100)
Number of subjects: 60
Study 2408513 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline control
Number of subjects: 60
Study 2884862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirmenol 50 or 100 mg intravenously
Number of subjects: 40
Study 2884862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28952457 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face education (10 minutes)
Number of subjects: 0
Study 28952457 — intervention group
Group type: COMPARATOR
Intervention: No specific education
Number of subjects: 0
Study 27831492 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of active treatment (WAT)
Number of subjects: 2779
Study 26608649 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program (calorie restriction of 100-150 kcal/day, fat-free vegetables, salt diet, optimum physical activity)
Number of subjects: 97
Study 26608649 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program
Number of subjects: 97
Study 23673893 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk-reduction intervention
Number of subjects: 349
Study 21420106 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 °C bypass temperature
Number of subjects: 66
Study 18499600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 0.5 microg/kg
Number of subjects: 96
Study 18499600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 microg/kg
Number of subjects: 96
Study 18499600 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 96
Study 16586550 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor (omeprazole or lansoprazole), clarithromycin, bismuth citrate and tinidazole
Number of subjects: 48
Study 16586550 — intervention group
Group type: COMPARATOR
Intervention: Protective agent of gastric mucosa (tepretone)
Number of subjects: 48
Study 14623508 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife education and support for smoking behaviour change
Number of subjects: 27
Study 14623508 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife's approach to smoking cessation
Number of subjects: 27
Study 10882825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (125mg/day for weeks 1-3, 250mg/day for weeks 4-7, 500mg/day for weeks 8-12)
Number of subjects: 86
Study 10882825 — intervention group
Group type: COMPARATOR
Intervention: Fructose (50g/day)
Number of subjects: 86
Study 8808130 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg fluvoxamine
Number of subjects: 12
Study 8808130 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg fluvoxamine
Number of subjects: 12
Study 8808130 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg dothiepin
Number of subjects: 12
Study 8808130 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 1434656 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal esophagectomy (THE)
Number of subjects: 55
Study 1434656 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic esophagectomy (TTE)
Number of subjects: 55
Study 3908504 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acyclovir
Number of subjects: 43
Study 31864068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal tDCS applied to the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 45
Study 31864068 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 45
Study 30275528 — intervention group
Group type: EXPERIMENTAL
Intervention: S-HAM (dose-dense induction)
Number of subjects: 387
Study 30275528 — intervention group
Group type: COMPARATOR
Intervention: Standard double induction (TAD-HAM or HAM)
Number of subjects: 387
Study 27586232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Magnesium (Mg)
Number of subjects: 261
Study 27586232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 25188444 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive fibrosis score (NFS)
Number of subjects: 104
Study 25188444 — intervention group
Group type: COMPARATOR
Intervention: APRI
Number of subjects: 104
Study 25188444 — intervention group
Group type: COMPARATOR
Intervention: FIB4
Number of subjects: 104
Study 25188444 — intervention group
Group type: COMPARATOR
Intervention: Forns
Number of subjects: 104
Study 22610193 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control (80-110 mg/dL)
Number of subjects: 13
Study 22610193 — intervention group
Group type: COMPARATOR
Intervention: Loose glycemic control (120-150 mg/dL)
Number of subjects: 13
Study 20406576 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (gluten- and casein-free diet)
Number of subjects: 72
Study 20406576 — intervention group
Group type: COMPARATOR
Intervention: Non-diet control group
Number of subjects: 72
Study 18566179 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Cutting Balloon Angioplasty (PCBA)
Number of subjects: 40
Study 18566179 — intervention group
Group type: COMPARATOR
Intervention: Conventional Balloon Angioplasty (CBA)
Number of subjects: 40
Study 18566179 — intervention group
Group type: EXPERIMENTAL
Intervention: PCBA
Number of subjects: 40
Study 18566179 — intervention group
Group type: COMPARATOR
Intervention: CBA
Number of subjects: 40
Study 16011610 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphtheal (5% amlexanox paste) during prodromal stage of RAU
Number of subjects: 0
Study 16011610 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphtheal (5% amlexanox paste) after ulcer development
Number of subjects: 0
Study 12448895 — intervention group
Group type: EXPERIMENTAL
Intervention: Porter/Brown scavenger system
Number of subjects: 0
Study 12448895 — intervention group
Group type: EXPERIMENTAL
Intervention: Accutron scavenger system
Number of subjects: 0
Study 12448895 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrx scavenger system
Number of subjects: 0
Study 12448895 — intervention group
Group type: COMPARATOR
Intervention: Control (no device)
Number of subjects: 0
Study 10898119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 2.5 mg
Number of subjects: 14
Study 10898119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 14
Study 10898119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 14
Study 10898119 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 14
Study 10898119 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 20 mg
Number of subjects: 14
Study 10898119 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 40 mg
Number of subjects: 14
Study 10898119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8653874 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (500 mg IV as a single bolus)
Number of subjects: 22
Study 8653874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1558796 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative chemotherapy including mitomycin C (MMC), OK‐432, UFT, PSK, and 5‐fluorouracil (5‐FU) bolus injections for 5 days starting on postoperative day 2
Number of subjects: 162
Study 1558796 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving therapy with MMC, OK‐432, UFT, PSK without 5‐FU
Number of subjects: 162
Study 4026911 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin (4 g, intravenous infusion over 5, 15, and 30 min)
Number of subjects: 3
Study 4026911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (4 g, intravenous infusion over 5, 15, and 30 min)
Number of subjects: 3
Study 4026911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both azlocillin and mezlocillin (4 g, intravenous infusion)
Number of subjects: 3
Study 31859723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial cellulose biopolymer film and gel dressing
Number of subjects: 24
Study 31859723 — intervention group
Group type: COMPARATOR
Intervention: Essential fatty acids (Control)
Number of subjects: 24
Study 30408642 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA cathodal tDCS (c-tDCS2mA)
Number of subjects: 0
Study 30408642 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 30408642 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS or 1 mA tDCS
Number of subjects: 0
Study 30408642 — intervention group
Group type: COMPARATOR
Intervention: c-tDCS2mA over a control site
Number of subjects: 0
Study 27378086 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-O (CHOP with ofatumumab)
Number of subjects: 43
Study 25757446 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rectal diclofenac
Number of subjects: 144
Study 25757446 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 144
Study 23691702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized whole milk
Number of subjects: 60
Study 23691702 — intervention group
Group type: EXPERIMENTAL
Intervention: UHT whole milk
Number of subjects: 60
Study 23691702 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 60
Study 23691702 — intervention group
Group type: COMPARATOR
Intervention: Diluted iodine contrast
Number of subjects: 60
Study 19952806 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking (60 min at 7.0 ± 0.1 km/h)
Number of subjects: 14
Study 19952806 — intervention group
Group type: COMPARATOR
Intervention: Control (resting for 8 hours)
Number of subjects: 14
Study 18799996 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine performance bar (CAF)
Number of subjects: 24
Study 18799996 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric noncaffeine performance bar (CHO)
Number of subjects: 24
Study 18799996 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (BEV)
Number of subjects: 24
Study 16015255 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene and retinol (vitamin A)
Number of subjects: 1845
Study 16015255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1845
Study 12551869 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake (5 categories: no alcohol or <1 drink monthly, 1 to 3 drinks monthly, 1 to 4 drinks weekly, 5 to 7 drinks weekly, > or =2 drinks daily)
Number of subjects: 2833
Study 12551869 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 2833
Study 12551869 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 2833
Study 11783211 — intervention group
Group type: EXPERIMENTAL
Intervention: Longhu Xingnao Granule (LHXNG) after light puncture
Number of subjects: 50
Study 11783211 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 50
Study 10155675 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0
Study 10155675 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine plus metoclopramide
Number of subjects: 0
Study 1842215 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 600 mg
Number of subjects: 80
Study 1842215 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone 300 mg
Number of subjects: 80
Study 1842215 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone 600 mg
Number of subjects: 80
Study 6786129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate (SCG)
Number of subjects: 0
Study 6786129 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sodium cromoglycate (SCG)
Number of subjects: 0
Study 31452425 — intervention group
Group type: EXPERIMENTAL
Intervention: FESS combined with PNN
Number of subjects: 85
Study 31452425 — intervention group
Group type: COMPARATOR
Intervention: FESS alone
Number of subjects: 85
Study 28550963 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video and prompt list intervention
Number of subjects: 259
Study 28550963 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 259
Study 25885285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (monotherapy)
Number of subjects: 289
Study 25885285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (combination therapy)
Number of subjects: 289
Study 23746110 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat therapy
Number of subjects: 60
Study 23746110 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 21466743 — intervention group
Group type: EXPERIMENTAL
Intervention: Full conditions (after consuming breakfast)
Number of subjects: 27
Study 21466743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry conditions (after an overnight fast)
Number of subjects: 27
Study 21466743 — intervention group
Group type: COMPARATOR
Intervention: All foods except banana
Number of subjects: 27
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life in Reflux and Dyspepsia food/drink problems
Number of subjects: 217
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life in Reflux and Dyspepsia vitality
Number of subjects: 217
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment-GERD workdays with reflux symptoms
Number of subjects: 217
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of heartburn
Number of subjects: 217
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of acid reflux
Number of subjects: 217
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Global rating of change in stomach problems
Number of subjects: 217
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment-GERD hours absent at work
Number of subjects: 217
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment-GERD reduced productivity at work
Number of subjects: 217
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Productivity and Activity Impairment-GERD reduced productivity during other activities
Number of subjects: 217
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional global rating of change
Number of subjects: 217
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gamble
Number of subjects: 217
Study 18619804 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling thermometer
Number of subjects: 217
Study 17497439 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus 1 ng/kg/min iloprost
Number of subjects: 20
Study 17497439 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study 15059371 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Unit (SU)
Number of subjects: 285
Study 11486442 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 22
Study 11486442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9755350 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program for inhaler medication compliance (6 weeks)
Number of subjects: 55
Study 7663491 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (0.2 mg salbutamol plus 0.2 mg budesonide t.i.d.)
Number of subjects: 116
Study 7663491 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (0.2 mg salbutamol plus placebo t.i.d.)
Number of subjects: 116
Study 7663491 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group follow-up (28-36 months)
Number of subjects: 116
Study 7663491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation group (decrease and stop corticosteroid after 2 months)
Number of subjects: 116
Study 7663491 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous group (continued treatment)
Number of subjects: 116
Study 2562087 — intervention group
Group type: EXPERIMENTAL
Intervention: pH adjusted 2% mepivacaine solution (pHAS)
Number of subjects: 200
Study 2562087 — intervention group
Group type: COMPARATOR
Intervention: Standard 2% mepivacaine solution
Number of subjects: 200
Study 368743 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogens (single oral doses)
Number of subjects: 0
Study 31996920 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 3352015
Study 31996920 — intervention group
Group type: COMPARATOR
Intervention: No Oseltamivir (Control)
Number of subjects: 3352015
Study 31022403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (120 mg subcutaneously every 4 weeks)
Number of subjects: 175
Study 31022403 — intervention group
Group type: COMPARATOR
Intervention: Standard care (blood pressure control, sodium-restricted diet, antihypertensive agents)
Number of subjects: 175
Study 31022403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 175
Study 28669885 — intervention group
Group type: EXPERIMENTAL
Intervention: EA (primary activation of TEA)
Number of subjects: 45
Study 28669885 — intervention group
Group type: COMPARATOR
Intervention: LA (no intraoperative activation of TEA)
Number of subjects: 45
Study 25419678 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural α‐TOH supplementation (n=40)
Number of subjects: 109
Study 25419678 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic α‐TOH supplementation (n=33)
Number of subjects: 109
Study 25419678 — intervention group
Group type: COMPARATOR
Intervention: Control without supplementation (n=36)
Number of subjects: 109
Study 25013762 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare program with 24 hours of consultation services via a health communication center (Group 2)
Number of subjects: 298
Study 25013762 — intervention group
Group type: COMPARATOR
Intervention: Public health nurse consultation at outpatient clinic (Group 1)
Number of subjects: 298
Study 25013762 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 298
Study 22994935 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-stabilized highly cross-linked polyethylene cemented cup
Number of subjects: 0
Study 22994935 — intervention group
Group type: COMPARATOR
Intervention: Conventional cross-linked polyethylene cemented cup
Number of subjects: 0
Study 22994935 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 18413439 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy at -110 degrees C
Number of subjects: 55
Study 18413439 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy at -60 degrees C
Number of subjects: 55
Study 18413439 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cold therapy between -20 degrees C and -30 degrees C
Number of subjects: 55
Study 18413439 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy at -110 degrees C with glucocorticoids (GC)
Number of subjects: 55
Study 18413439 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy at -60 degrees C with glucocorticoids (GC)
Number of subjects: 55